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Abstract
Background: NSAIDs exhibit protective properties towards some cancers, especially colon cancer. Yet, it is not
clear how they play their protective role. PGE2 is generally shown as the only target of the NSAIDs anticancerous
activity. However, PGE2 known targets become more and more manifold, considering both the molecular pathways
involved and the target cells in the tumour. The role of PGE2 in tumour progression thus appears complex and
multipurpose.
Methods: To gain understanding into the role of PGE2 in colon cancer, we focused on the activity of PGE2 in
apoptosis in colon cancer cell lines.
Results: We observed that an increase in intracellular PGE2 induced an apoptotic cell death, which was dependent
on the expression of the proapoptotic protein Bax. This increase was induced by increasing PGE2 intracellular
concentration, either by PGE2 microinjection or by the pharmacological inhibition of PGE2 exportation and
enzymatic degradation.
Conclusions: We present here a new sight onto PGE2 in colon cancer cells opening the way to a new prospective
therapeutic strategy in cancer, alternative to NSAIDs.
Background
Prostaglandins are implicated in a wide range of physio-
logical and pathological pathways. Among these path-
ways, cancer occurrence and development is one of the
most debated. It is undoubtable that NSAIDs use was
shown to reduce the incidence of some cancers [1],
among which colon cancer took the highest therapeutic
advantage [1]. It is unclear, however, how NSAIDs play
their protective role. At the tissue level, chronic inflam-
mation is implicated in the development of cancers [2].
Proinflammatory prostaglandins play a role in tumour
progression in many ways, namely cell proliferation, sur-
vival and migration, immunosuppression and angiogen-
esis [2]. The anti-inflammatory activity of NSAIDs is
thus probably involved in their anti-cancer potency. Yet,
at the cellular level, the mechanism by which NSAIDs
exert their proapoptotic activity is not clear. PGE2 itself
has been shown to play various roles in cell survival and
proliferation (reviewed in [3]). PGE2 induces the activa-
tion of several pathways in cancer cells through its
interaction with membrane receptors EP(1-4) [3], and
nuclear receptors (PPARδ) [4], thereby promoting prolif-
eration and survival. Besides, 15-PGDH, the enzyme
responsible for its degradation, has been identified as a
negative regulator of colon cancer progression [5].
Nevertheless, some models demonstrate a more complex
role played by PGE2, since it induces cell death under
some circumstances. Thus, it was shown that PGE2
could mediate both neuroprotection and neurotoxicity
through the same EP2 receptor, depending on the con-
ditions [6]. Huang and colleagues also demonstrated an
EP2/EP4-mediated apoptotic role of PGE2 in fibroblasts
[7]. Moreover, PGE2 was also shown to exert opposite
effects on colon cancer cells proliferation through differ-
ent signalling pathways depending on the range of its
concentration in the cell culture [8].
Strikingly, although NSAIDs modulate the production
of several prostaglandins, their inhibiting efficiency is
classically monitored by the sole measurement of PGE2
secretion. This consideration is very restrictive, since it
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is known that many processes are regulated by the
balance between PGE2 and PGD2, which is also pro-
duced downstream of COX-2. Moreover, PGE2 secretion
does not strictly reflect PGE2 production since it
excludes PGE2 intracellular accumulation and/or degra-
dation. Interestingly, two groups published their results
in APCMin/+ mice demonstrating on the one hand that
the genetic deletion of mPGES-1, the terminal enzyme
responsible for PGE2 synthesis, increased intestinal
tumorigenesis [9], while on the other hand PGE2 treat-
ment induced a raise in intestinal adenoma growth [4].
This apparent discrepancy suggests that PGE2 effects in
intestinal tumorigenesis might not be restricted to those
observed with extracellular provision.
Besides, we have observed in the glioblastoma [10]
that the overexpression of mPGES-1 was correlated to a
longer survival of patients. We have shown in glioblas-
toma that intracellular PGE2 induced a direct activation
of the pro-apoptotic protein Bax, thereby inducing glio-
blastoma cells apoptosis [10], whereas extracellular
PGE2 did not. The role played by PGE2 in cancer thus
appears highly complex, whether in the whole tissue or
even in isolated cancer cells. To gain understanding in
the signalling of PGE2 in colon cancer cells, we focussed




Cell culture material was obtained from Gibco (Invitro-
gen, Cergy Pontoise, France). Unless mentioned, chemi-
cal products and reagents were obtained from Sigma
(France).
Antibodies were purchased from indicated companies:
COX-2 (Cayman, #160107), mPGES-1 (Cayman, #160140),
actin (Chemicon, #MAB1501R).
15-PGDH inhibitor (CAY10397) was purchased from
Cayman (#70130) (Interchim, France).
3H-PGE2 (0.1 μCi/μl) was purchased from Amersham
Biosciences.
Immunoblots were quantified using the ImageJ soft-
ware (NIH, USA).
Every experiment was repeated at least 3 independent
times unless otherwise stated.
Statistical analyses were performed using the Graph-
Pad software (San Diego, CA 92130 USA) (Student
unpaired t-test, *: p < 0.05, **: p < 0.01).
Patients
Patient materials as well as records (diagnosis, age, sex,
date of death) were used with confidentiality according
to French laws and recommendations of the French
National Committee of Ethic. Tumor samples were col-
lected from adult patients after surgical resection at the
Department of anatomo-pathology of the Hospital of
Nantes over the years 2002-2003. The clinical informa-
tion of the patients is summarized in additional file 1
table SI, and additional file 2 table SII. Control tissue
was obtained from normal colon tissue found at the per-
iphery of the resected tumor.
RT-PCR
Cells were washed twice in PBS, then total RNA was iso-
lated using the RNAwiz (Ambion, Austin, TX, USA)
according to the manufacturer’s instructions with DNAse
I treatment. After RNA quantification using the Nano
Drop (Nano Drop ND-1000, Thermo Fisher Scientific,
Waltham, MA, USA), the quality of the RNA was deter-
mined in an Agilent 2100 Bioanalyzer (Agilent, Palto
Alto, CA, USA) using the Labchip RNA 6000 kit. A mini-
mum RNA Integrity Number (RIN) value of 8 was
required [11]. Total RNA (1 μg) was reverse transcribed
in a final volume of 20 μl using the Superscript II kit
(Invitrogen, France). Subsequently the cDNA was diluted
to a final concentration of 20 ng/μl, for use in Q-PCR.
The PCR reaction contained 40 ng cDNA in a reac-
tion volume of 25 μl, 1× Brilliant II SYBR Green Q-PCR
master mix, 200 nM reverse and forward primers and
30 nM Sybr Green. Thermo-cycling conditions were
95°C for 10 min followed by 40 cycles at 95°C for 1
min, 60°C for 45 s and 72°C for 30 s. Gene expression
values were normalized to housekeeping gene (GAPDH)
and relative expression values were calculated based on
the comparative ∆∆CT-method with adherent cells used
as a reference for each cell type[12].
GAPDH: sense primer: 5’-GAAGGTGAAGGTCG-
GAGTC-3’
antisense primer: 5’-GAAGATGGTGATGGGATTTC-3’
COX-2: sense primer: 5’-CAGCCATACAG-
CAAATCC-3’
antisense primer: 5’-ATCCTGTCCGGGTACAAT-3’
mPGES-1: sense primer: 5’-AGGAAGACCAG-
GAAGTGC-3’
antisense primer: 5’-ACGACATGGAGACCATCTAC-3’
MRP4: sense primer: 5’-AAGTGAACAACCTC-
CAGTTCCA-3’
antisense primer: 5’-CCGGAGCTTTCAGAATTGAC-3’




Cell culture and transfection
HCT-116 and HCT-116Bax-/- cells (described in [13])
were grown in McCOY’s 5A medium containing 10%
fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin. SW1116 cells were grown
in RPMI medium containing 10% fetal calf serum,
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2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin. The cells were transfected by a plasmid
encoding for the sequence of mPGES-1 cDNA sub-
cloned into pDEST12.2 vector (Invitrogen), or by the
mock plasmid containing no coding sequence [10].
Plasmid DNA (5 μg) was introduced into 106 cells by
electroporation (GenePulser, Bio-Rad) using 200 V/cm
and 250 μF. Transfected cells were selected and further
cultured in a medium containing 1 mg/ml G418. The
mock-transfected cells were used as a control for the
mPGES-1 transfected cells in the expression and viabi-
lity experiments.
Microinjection experiments
Microinjection was performed as described by Cartron
et al. [14]. PGE2 was co-injected with a dextran coupled
to a fluorochrome (Oregon Green, Molecular Probes).
The instantaneous intracellular concentration of com-
pounds achieved by the microinjection is about one tenth
of the initial concentration in the injected solution. The
percentage of fluorescent cells exhibiting morphological
apoptotic features was evaluated every hour following
PGE2 microinjection using an inverted fluorescent micro-
scope (DMIRE2, Leica France).
3H-PGE2 internalisation assay.
HCT-116Bax-/- cells were seeded in a 96-well culture
plate the day before experiment. 5 μl 3H-PGE2 was
added to the cells. Inhibitors of 15-PGDH (CAY10397,
15 μM) and MRP4 (ketoprofen, 1 μM [15]) were
added in every other well. After the indicated incuba-
tion time (0 min, 30 min and 1 h), cells were rinsed
and harvested. The amount of radiolabeled PGE2 pre-
sent in the cells was quantified by beta-emission mea-
surement (LS 6500 liquid scintillation counter,
Beckman Coulter).
Caspase activation assay
Total cell lysates were carried out with RIPA buffer
(PBS, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS,
proteases inhibitor cocktail (Roche, Meylan, France))
and protein concentrations were measured by the Brad-
ford technique. DEVDase activity was measured using
the fluorometric CaspACE Assay System (Promega) and
normalized to the sample protein concentration as
described previously [10].
Western blot
Total cell lysates were obtained with RIPA buffer and
separated by SDS-PAGE. Proteins were transferred onto
PVDF membranes by semi-dry transfer. Membranes
were successively probed with the indicated antibodies
and revealed by ECL with peroxidase-coupled secondary
antibodies.
Viability assays
SW1116 cells were plated the day before treatment.
PGE2 (10 μM) was added to the culture medium. After
10 min, CAY10397 (15 μM) and ketoprofen (1 μM)
were added, and cells were treated for 30 h. Cell death
was then assessed by trypan blue staining.
Results
Heterogeneity of COX-2 and mPGES-1 expression in
human colon cancer
The role played by PGE2 in cell survival/proliferation or
in cell death is still highly debated. Given the observa-
tion we made in glioblastoma that mPGES-1 overexpres-
sion was correlated to an increased survival of patients,
we studied the expression of COX-2 and mPGES-1 in
nine human colon cancer samples (Figure 1A). mPGES-
1 expression was very inconstant in the tumours, some
expressing very high levels of the protein whereas
mPGES-1 was hardly detectable in others. COX-2
expression was weakly detected in all the samples. We
then measured mPGES-1 and COX-2 transcripts in
seven additional human colon cancer samples and in
the non cancerous corresponding tissue by qPCR
(Figure 1B). Similarly, mPGES-1 expression appeared
very inconstant whereas COX-2 was regularly overex-
pressed in cancer tissue compared to control (p < 0.003
in 5 out of 7 patients), even if the mRNA relative
expression level was low (see mPGES-1, left graph, for
comparison). Of note, in two out of three tumours over-
expressing mPGES-1, COX-2 was largely overexpressed.
In our hands, it thus seems that mPGES-1 was not
always up-regulated in colon cancers.
Effect of mPGES-1 overexpression in human colon cancer
cell lines
We have previously shown in glioblastoma primary
cultures that mPGES-1 exogenous overexpression sen-
sitized the cells to apoptosis [10]. We thus considered
if this observation could be reproduced in human
colon cancer cells in vitro, when isolated from the
stroma. We first analysed the expression of mPGES-1
and COX-2 in two model human colon cancer cell
lines (HCT-116 and SW1116). As shown in Figure 2A,
mPGES-1 expression was hardly detectable in both cell
lines (Figure 2A right, lanes 1 and 3). In contrast,
COX-2 was abundantly expressed in SW1116 cells, but
not in HCT-116 cells. HCT-116 cells have often been
presented as COX-2 deficient cells, whereas they rather
seem to constitutively express COX-2, unlike non-
cancer cells, even at lower level than other cell lines.
We induced mPGES-1 overexpression in both cell
lines by plasmid transfection. Of note, two rounds of
transfection were necessary to induce a steady expres-
sion of mPGES-1 in HCT-116 cells. As we had
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observed earlier in glioblastoma cells, the modulation
of mPGES-1 expression had an effect on the expres-
sion of COX-2. Surprisingly, COX-2 expression was
increased in HCT-116 cells overexpressing mPGES-1
whereas it was not significantly modified in SW1116
transfected cells (Figure 2A left, lanes 2 and 4). We
verified that the transfection of mPGES-1 in these two
cell lines and in two additional colon cell lines (HCT-8
and HT29) was accompanied by an increase in intra-
cellular PGE2 concentration (additional file 3 figure
S1A). Since the expression of COX-2 was not modified
by the transfection in SW1116 cells, we used these
cells for the rest of the experiment. SW1116 cells were
subjected to UV-B irradiation to induce apoptosis (25
J/cm2, 10 min). The specific caspase-3 activity was
measured in the cell lysate after 30 hours. As shown in
Figure 2B, mPGES-1 overexpression led to a higher
caspase-3 activity, attesting to a higher sensitivity of
the cells to apoptosis induction. Of note, we measured
a constitutive caspase-3 activity in all the four mPGES-
1-transfected cells, even if this activity was very low
and was not associated to a significant cell death (addi-
tional file 3 figure S1B).
Effect of PGE2 microinjection in colon cancer cell
The conflicting observations that extracellular PGE2
promotes colon cancer cells survival and proliferation
[3,4,8] while mPGES-1 overexpression increases apopto-
sis in colon cancer cells (Figure 2B andadditional file 3
figure S1B) prompted us to study the effect of PGE2
microinjection directly into the cytoplasm of colon can-
cer cells. The treatment of the four colon cancer cell
lines with PGE2 extracellular concentrations ranging
from 0.1 μM to 100 μM induced no more than 10% cell
death compared to control cells. Yet HCT-116 cells
exhibited the highest variation coefficient in cell death
following to PGE2 extracellular treatment (additional file
4 figure S2). As shown in Figure 3A, PGE2 microinjec-
tion induces a significant cell death within 5 hours in
both SW1116 and HCT-116 cell lines, whereas SW1116
cells are only sensitive to the highest concentration
injected (left). Of note, the microinjection of a 20 μM
PGE2 solution results in a transient intracellular increase
of about 2 μM, which is consistent with the intracellular
levels we have previously measured during apoptosis
induction (unpublished results). Consistent with the
direct effect of PGE2 on Bax activation we have
Figure 1 Expression of mPGES-1 and COX-2 in human colon cancer tissues. A: mPGES-1 and COX-2 expression were detected by western
blot in 9 human colon cancer protein extracts. Band intensity was quantified and normalized to the corresponding intensity of actin in the
sample. B: The expression of mPGES-1 and COX-2 transcripts was measured by RT-PCR in cDNA samples from 7 patients including paired normal
and tumour colon tissues and normalized to GAPDH transcript. The significance of the difference between tumour and control tissue is indicated
in brackets when the transcript is down-regulated in tumour.
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previously demonstrated, we observed that the cell death
induced by PGE2 in colon cancer cells was dependent on
Bax expression. Indeed, Bax-deficient HCT-116Bax-/- cells
appeared resistant to PGE2 microinjection (Figure 3B).
Effect of PGE2 intracellular accumulation induced by
pharmacological agents.
Since PGE2 microinjection was able to induce colon
cancer cell death, whereas extracellular PGE2 could not,
we tried to force PGE2 cytoplasmic accumulation by
pharmacological means. PGE2 intracellular concentra-
tion is the result of several regulated processes, among
which are its synthesis, its enzymatic degradation
through the activity of 15-PGDH (15-prostaglandin E2
dehydrogenase), and its membrane transport, mainly
through the export protein MRP4. We thus analysed the
level of the transcripts of the synthesis enzymes COX-2
and mPGES-1 and also those of 15-PGDH and MRP4 in
both cell lines HCT-116 and SW1116 (Figure 4A). It
was noticeable that SW1116 cells expressed a high level
of 15-PGDH compared to HCT-116, possibly explaining
the significant difference of sensitivity to PGE2 microin-
jection (Figure 3A). Ketoprofen was used, at a non-
COX-2 inhibiting dose, to block the MRP4-mediated
exportation of PGE2 [15], while CAY10397 was used to
inhibit PGE2 enzymatic degradation by 15-PGDH.
Treating the cells with both drugs caused a significant
cytoplasmic accumulation of 3H-PGE2, as measured in
the resistant HCT-116Bax-/- cells (Figure 4B, black
squares), whereas 3H-PGE2 remained extracellular in the
absence of MRP4 inhibition (Figure 4B, open circles).
Given this result, we treated SW1116 cells with extracel-
lular PGE2 and with various combinations of the inhibi-
tors described and measured cell death after 30 hours
by Trypan blue exclusion. As shown in Figure 4C, the
combination of both inhibitors induced a significant cell
Figure 2 Expression of mPGES-1 in colon cancer cell lines. A: mPGES-1 and COX-2 expression were detected by western blot in the colon
cancer lines HCT-116 and SW1116, either mock-transfected or overexpressing mPGES-1 (HCT-116/PGES and SW1116/PGES respectively). The
bands intensity was quantified and normalized to the corresponding intensity of actin in the sample (graph). B: mock-transfected SW1116 cells
and SW1116 cells overexpressing mPGES-1 were submitted to UV-B irradiation and DEVDase activity was measured in the cell lysate after 30 h as
described earlier [10].
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death even in the absence of exogenous PGE2. However,
cell death increased from 21 to 38% when PGE2 was
added. A significant, yet slightly lower cell death induc-
tion was observed when either CAY10397 or ketoprofen
was omitted, indicating that both PGE2 enzymatic
degradation and exportation participate in the survival
of these. We verified in SW1116 cells that the treatment
applied effectively induced an increase in PGE2 intracel-
lular concentration and that caspase 3 was activated,
testifying apoptotic cell death (additional file 5 figure
S3A). Of note, the treatment described above also
enabled PGE2 intracellular accumulation and cell death
in the three additional colon cell lines used (additional
file 5 figure S3B); besides, we confirmed the singularity
of HCT-116 cells compared to the three other cell lines
since PGE2 internalisation was measured even in the
absence of the inhibitors, making their sensitivity to
extracellular PGE2 clearer. We also verified, using the
HCT-116 cell line and its Bax-deficient counterpart
(HCT-116Bax-/-), that the cell death induced by the com-
bination of extracellular PGE2 and the inhibitors
described above was Bax-dependent (Figure 4D).
Discussion
An extensive amount of data point out that COX-2 and
its product PGE2 are actors of cancer promotion and
progression. This point has been supported by the fact
that the use of COX inhibitors reduces the incidence of
several cancers, among which colorectal cancer [1].
Mechanistically, it has been established that PGE2, one
Figure 3 Effect of PGE2 cytoplasmic microinjection. A: SW1116 and HCT-116 cells were microinjected with PGE2 as described in the material
and methods section. The graph represents the amount of dead cells among the microinjected population over the time. B: PGE2 microinjection
was performed in HCT-116 and HCT-116Bax-/- cells as in A.
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of the products of COX-2 activity, could activate several
pathways implicated in cancer, namely apoptosis eva-
sion, cell proliferation, migration and angiogenesis. The
majority of these effects are mediated through G-
coupled EP receptors (EP1-4) [2]. Nevertheless, conflict-
ing results tend to demonstrate that PGE2 is much
more versatile than what was initially thought.
Besides, caution should be used when considering
COX inhibitors as “anti-PGE2“ compounds. The inhibi-
tion of COX-2, even with the use of selective COX-2
inhibitors, definitely has larger consequences than a
decrease in PGE2 synthesis since several prostaglandins
arise from COX-2 activity. For instance, Thoren and
Jakobsson [16] demonstrated that COX-2 inhibitors had
a various ability to inhibit mPGES-1 activity. As a conse-
quence, COX-2 inhibitors not only modulate COX-2
activity but also the potential coupling of COX-2 and
mPGES-1 activity; they consequently not only modulate
PGH2 production but also the ratio between the PGH2
products, among which PGE2 and PGD2, which are
known to exert opposite effects on Bax activation [17].
Given the multiplicity of the physiological functions of
prostaglandins and the very subtle regulatory processes
which can hardly be predicted in the whole, we need a
deeper understanding of the pathways in which the pro-
ducts of COX are implicated in cell signalling, in the tis-
sue and in the body, before safely using NSAIDs as anti-
cancer therapeutic adjuvants. More disturbing is the
observation that the anti-proliferative effects of COX-2
inhibitors on cancer cells have also been demonstrated
in COX-2-deficient cells [18-21], suggesting that the
role of COX-2 and its product PGE2 in cancer might
have been overvalued based on the effects of pharmaco-
logical COX-2 inhibitors.
Figure 4 Effect of constraint PGE2 internalisation on cell viability. A: the normalized expression of COX-2, mPGES-1, MRP4 and 15-PGDH
transcripts were measured in HCT-116 and SW1116 cells. The graph shown is representative of 2 independent experiments. B: the internalisation
of 3H-PGE2 added in the medium in HCT-116
Bax-/- cells is shown. C: SW1116 cells were treated with the indicated combination of extracellular
PGE2 and inhibitors and cell death was assessed by Trypan blue exclusion. D: HCT-116 and HCT-116
Bax-/- cells were treated by 10 μM PGE2 with
or without both inhibitors and cell death was assessed by Trypan blue exclusion.
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We show here that the overexpression of mPGES-1,
the enzyme responsible for PGE2 synthesis downstream
of COX-2, sensitizes isolated colon cancer cells to apop-
tosis in vitro. We also demonstrate that cell death can
be induced in colon cancer cells by increasing the intra-
cellular content in PGE2, either through direct microin-
jection or through the inhibition of PGE2 intracellular
exportation and degradation, provided the cells express
the protein Bax. Indeed, taking into account the data of
Reid and colleagues [15], which showed that several
NSAIDs exert an inhibitory activity on MRP4 at concen-
trations inferior to those used for COX inhibition, we
showed that ketoprofen could induce a PGE2-dependent
cell death, even if MRP4 inhibition might inhibit the
efflux of other compounds from the cells; this could
partly explain the disastrous cardiac side effects
observed during long-term NSAID treatments. Similarly,
we did not explore the consequence of 15-PGDH inhibi-
tion on the concentration of other prostaglandins, but
we showed that the cell death was considerably
increased by the adding of PGE2 in the cell culture,
demonstrating that PGE2 was at least partly responsible
for the apoptosis induced. These results are consistent
with what we have previously described in glioblastoma
[10]. To our comprehension, our results also bring a
possible explanation to some of the conflicting results
observed between extracellular PGE2 treatments and
modulations of PGE2 production (see [4] and [9] for
example). With the care to be as representative as possi-
ble for colon cancers, our in vitro work was realised
with four colon cancer cell lines, two of which presented
LOH (SW1116 and HT29) whereas the other two were
classified MSI-positive (HCT-116 and HCT-8)[22,23].
What could be the rationale of these ambiguous prop-
erties exhibited by PGE2? An attractive concept was
recently described by Li and colleagues [24]. They report
that executive caspases, key players of apoptotic cell
death, are necessary for wound healing. The activation
of these caspases in injured cells is responsible for PGE2
synthesis and exportation. When released at the
wounded site, PGE2 stimulates stem cells proliferation
and tissue regeneration. PGE2 might thus be regarded as
a danger signal emerging from dying cells. Our under-
standing of the mechanism is that newly produced,
intracellular PGE2 is able to sensitize the cells to death
through the activation of the apoptotic protein Bax. In
the cells where the death signals overwhelm the resis-
tance capacities, caspases are activated and apoptosis
occurs. Meanwhile, PGE2 production and release in the
environment is increased; PGE2 thus exerts its antiapop-
totic, proliferative and migratory role on the neighbour-
ing cells through the EP receptors pathway. In the
context of a tumour, the surviving cells become more
resistant to a subsequent insult. PGE2 activity in tumour
cells would thus follow a two-step mechanism: first,
intracellular PGE2 participates in apoptotic cell death;
second, secreted PGE2 has an autocrine or paracrine
protective and stimulating activity, respectively on the
producing cell if the integration of death signals is com-
patible with survival, or on the neighbouring cells if cell
death is induced, with an amplification loop in PGE2
production through executive caspases activity. The
important consequence of this mechanism is that PGE2
exportation from cancer cells is the most detrimental
determinant in the role played by PGE2 in tumour pro-
gression. An alternative to COX-2 inhibitors as adjuvant
anti-cancer therapies might thus be the use of drugs
inhibiting PGE2 efflux from the cancer cells. The poten-
tial of MRP4 inhibitors in enhancing classical therapies
would thereby be worth questioning.
Conclusions
Our present work demonstrates that intracellular PGE2
can exert a pro-apoptotic, Bax-dependent apoptosis in
colon cancer cell lines in vitro. We thereby bring an
additional level of complexity in the highly complex role
played by PGE2 in colon cancer progression. We also
suggest that MRP4 inhibition might be a valuable adju-
vant strategy to colon cancers treatments.
Additional material
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Additional file 2: table SII. clinical information of the second set of
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Additional file 4: figure S2. effect of extracellular PGE2 on the 4 colon
cancer cell lines viability.
Additional file 5: figure S3. extracellular PGE2 internalisation in the 4
colon cancer cell lines.
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